Lipoprotein (a)-We know so much yet still have much to learn . . .

Journal of the American Heart Association

Volumn 5, Issue 4, 2016, Pages

  Banach, Maciej ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Editorials; Lipids; Lipoprotein; Myocardial infarction

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B100; BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MEGALIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN RECEPTOR; RECEPTOR; SCAVENGER RECEPTOR BI; UNCLASSIFIED DRUG; LIPID; LIPOPROTEIN; LIPOPROTEIN A; TRIACYLGLYCEROL;

ABDOMINAL AORTA ANEURYSM; ACUTE CORONARY SYNDROME; AORTA STENOSIS; BINDING SITE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CELL PROLIFERATION; DISEASE ASSOCIATION; EDITORIAL; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; LIPOPROTEIN SECRETION; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; RISK REDUCTION;

LIPIDS; LIPOPROTEIN(A); LIPOPROTEINS; MYOCARDIAL INFARCTION; TRIGLYCERIDES;

EID: 84991258437     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.116.003597     Document Type: Editorial

References (18)

1. Banach M, Aronow WS, Serban C, Sahabkar A, Rysz J, Voroneanu L, Covic A. Lipids, blood pressure and kidney update 2014. Pharmacol Res. 2015;95- 96:111-125.
2. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844-2853.
3. Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/ kexin type 9 through the low density lipoprotein receptor. J Biol Chem. 2015;290:11649-11662.
4. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein (a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90:52-60.
5. Banach M, Aronow WS, Serban MC, Rysz J, Voroneanu L, Covic A. Lipids, blood pressure and kidney update 2015. Lipids Health Dis. 2015;14:167.
6. Davidson MH, Ballantyne CM, Jacobson TA, Bittner VA, Braun LT, Brown AS, Brown WV, Cromwell WC, Goldberg RB, McKenney JM, Remaley AT, Sniderman AD, Toth PP, Tsimikas S, Ziajka PE, Maki KC, Dicklin MR. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011;5:338-367.
7. Kotani K, Sakane N. Carotid intima-media thickness in asymptomatic subjects with low lipoprotein(a) levels. J Clin Med Res. 2012;4:130-134.
8. Ishikawa S, Kotani K, Kario K, Kayaba K, Gotoh T, Nakamura Y, Kajii E; Jichi Medical School (JMS) cohort study group. Inverse association between serum lipoprotein(a) and cerebral hemorrhage in the Japanese population. Thromb Res. 2013;131:e54-e58.
9. Kotani K, Sahebkar A, Serban MC, Ursoniu S, Mikhailidis DP, Mariscalco G, Jones SR, Martin S, Blaha MJ, Toth PP, Rizzo M, Kostner K, Rysz J, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Lipoprotein(a) levels in patients with abdominal aortic aneurysm: a systematic review and meta-analysis. Angiology. 2016; doi: 10.1177/0003319716637792. [Epub ahead of print].
10. Afshar M, Pilote L, Dufresne L, Engert JC, Thanassoulis G. Lipoprotein(a) interactions with low-density lipoprotein cholesterol and other cardiovascular risk factors in premature acute coronary syndrome (ACS). J Am Heart Assoc. 2016;5:e003012 doi: 10.1161/JAHA.115.003012.
11. Agouridis AP, Mikhailidis DP. Statins and niacin: the end of residual risk therapy? In: Banach M, ed. Combination Therapy in Dyslipidemia. 1st ed. Springer International Publishing: Switzerland, 2015:37-43.
12. Cannon CP, Dansky HM, Davidson M, Gotto AM Jr, Brinton EA, Gould AL, Stepanavage M, Liu SX, Shah S, Rubino J, Gibbons P, Hermanowski-Vosatka A, Binkowitz B, Mitchel Y, Barter P; DEFINE Investigators. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J. 2009;158:513-519.e3.
13. Serban MC, Banach M, Mikhailidis DP. Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options. Expert Opin Pharmacother. 2016;17:369-380.
14. Dragan S, Serban MC, Banach M. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy? J Cardiovasc Pharmacol Ther. 2015;20:157-168.
15. Kotani K, Sahebkar A, Serban C, Andrica F, Toth PP, Jones SR, Kostner K, Blaha MJ, Martin S, Rysz J, Glasser S, Ray KK, Watts GF, Mikhailidis DP, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Tibolone decreases lipoprotein(a) levels in postmenopausal women: a systematic review and meta-analysis of 12 studies with 1009 patients. Atherosclerosis. 2015;242:87-96.
16. Serban MC, Sahebkar A, Mikhailidis DP, Toth PP, Jones SR, Muntner P, Blaha MJ, Andrica F, Martin SS, Borza C, Lip GY, Ray KK, Rysz J, Hazen SL, Banach M; Impact of L-carnitine on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2016;6:19188.
17. Sahebkar A, Serban C, Ursoniu S, Banach M. Effect of garlic on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of randomized controlled clinical trials. Nutrition. 2016;32:33-40.
18. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331-2339.